Summary
AbbVie Inc. (ABBV) announced on February 26, 2024, that it has entered into an underwriting agreement to issue and sell $15.0 billion in aggregate principal amount of senior notes. These notes are offered in various denominations and maturities, ranging from 2027 to 2064, with coupon rates varying from 4.800% to 5.500%. This significant debt issuance is intended to strengthen AbbVie's financial position and fund key strategic initiatives. The primary uses of the net proceeds from this offering are to prepay a $5.0 billion term loan, the proceeds of which were used for the ImmunoGen acquisition, and to fund AbbVie's pending acquisition of Cerevel Therapeutics Holdings, Inc. Additionally, funds will be allocated to repay outstanding commercial paper borrowings and for general corporate purposes. This move indicates a proactive approach by AbbVie to manage its debt structure and finance its growth strategies.
Key Highlights
- 1AbbVie is issuing $15.0 billion in senior notes with maturities between 2027 and 2064.
- 2The senior notes carry interest rates ranging from 4.800% to 5.500%.
- 3Proceeds will be used to repay a $5.0 billion term loan related to the ImmunoGen acquisition.
- 4A significant portion of the funds will be used to finance the pending acquisition of Cerevel Therapeutics Holdings, Inc.
- 5The offering also aims to repay outstanding commercial paper borrowings.
- 6The notes are unsecured, unsubordinated obligations of AbbVie.
- 7The offering is being conducted through a registered public offering with multiple underwriters.